HGENQ Projected Dividend Yield
Humanigen Inc ( OTCBB : HGENQ )Humanigen is a clinical stage biopharmaceutical company, developing its portfolio of proprietary Humaneered® anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Co.'s proprietary Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Co.'s primary product candidate, lenzilumab, and its other product candidates, ifabotuzumab, are Humaneered monoclonal antibodies. Co.'s Humaneered antibodies are closer to human antibodies than chimeric or humanized antibodies and have a high affinity for their target. 20 YEAR PERFORMANCE RESULTS |
HGENQ Dividend History Detail HGENQ Dividend News HGENQ Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |